Dr. Kalia is a graduate of the MD/PhD program at the University of Toronto, where he entered the neurosurgery residency program. During his PhD he discovered novel molecular targets which contribute to the degeneration of dopaminergic neurons in Parkinson’s disease. He completed a postdoctoral research fellowship at the Massachusetts General Hospital Institute for Neurodegenerative Disease, Harvard University. He subsequently resumed residency training and graduated from the Toronto program in 2012 and became a Fellow of the Royal College of Physicians and Surgeons of Canada that year. From 2012-13, Dr. Kalia completed a clinical fellowship in functional and stereotactic neurosurgery at Toronto Western Hospital, and was recruited to the Division of Neurosurgery with a staff appointment at Toronto Western Hospital. He is appointed as an Assistant Professor in the Department of Surgery at the University of Toronto. He is an expert in using neuromodulation approaches for the surgical management of movement disorders, pain and epilepsy. His research laboratory is within the Krembil Research Institute and focuses on understanding molecular mechanisms of protein homeostasis in neurodegeneration and on establishing model systems to study novel applications of neuromodulation in diseases of the central nervous system.
Our current work is aimed at:
1. Understanding how chaperone molecules fail to maintain adequate protein quality control in Parkinson’s disease (PD) and other neurodegenerative disorders;
2. Dissecting molecular pathways that contribute to aberrant protein disposal via the proteasome and lysosomal systems in PD; and,
3. Developing innovative methods and novel applications of neuromodulation to target and regulate these protein quality control pathways in PD and other neurodegenerative disorders.
Our ultimate goal is to find ways to mitigate the loss of neurons in the brain to be able to slow or even halt the progression of PD and other neurodegenerative disorders.